Применение антиаритмических средств у пожилых пациентов. Препараты III и IV классов по классификации Вогана-Вильямса
https://doi.org/10.20996/1819-6446-2016-12-5-603-609
Аннотация
Эффективность антиаритмических препаратов у пожилых аналогична таковой у более молодых пациентов. Однако данные в отношении «очень пожилых» пациентов крайне ограничены. Вследствие возрастных изменений фармакокинетики, наличия сопутствующих заболеваний и лекарственных взаимодействий пожилые пациенты более уязвимы в отношении нежелательных реакций антиаритмических препаратов. Амиодарон в связи с высоким риском несердечных побочных эффектов не является препаратом выбора у пожилых пациентов. Другие препараты III класса следует назначать пожилым с большой осторожностью при тщательном наблюдении за лечением. Дилтиазем и верапамил не следует применять у лиц пожилого возраста с хронической сердечной недостаточностью III-IV класса по Нью-Йоркской классификации, а также одновременно с β-адреноблокаторами.
Об авторах
Е. А. Ушкалова
Российский университет дружбы народов. Россия, 117198, Москва, ул. Миклухо-Маклая, 6
Россия
Россия
д.м.н., профессор кафедры общей и клинической фармакологии РУДН
С. К. Зырянов
Российский университет дружбы народов. Россия, 117198, Москва, ул. Миклухо-Маклая, 6
Россия
Россия
д.м.н., заведующий кафедрой общей и клинической фармакологии РУДН
К. Э. Затолочина
Российский университет дружбы народов. Россия, 117198, Москва, ул. Миклухо-Маклая, 6
Россия
Россия
к.м.н., ассистент кафедры общей и клинической фармакологии РУДН
А. П. Переверзев
Российский университет дружбы народов. Россия, 117198, Москва, ул. Миклухо-Маклая, 6
Россия
Россия
к.м.н., доцент кафедры общей и клинической фармакологии РУДН
Н. А. Чухарева
Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Россия 117997, Москва, ул. Опарина, 4
Россия
Россия
м.н.с. терапевтического отделения, Научный центр акушерства, гинекологии и перинаталогии им. академика В.И. Кулакова
Список литературы
1. Sviridenko NY, Bokalov SA, Serdyuk SE, et al. The conditions caused by amiodarone, in practice, the cardiologist and endocrinologist. Lechacshii Vrach 2004; 2: 16-20. In Russian (Свириденко Н.Ю., Бокалов С.А., Сердюк С.Е. и др. Состояния, вызванные приемом амиодарона, в практике кардиолога и эндокринолога. Лечащий Врач 2004; 2: 16-20).
2. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):1312-22.
3. Kawabata M, Hirao K, Hachiya H, et al. Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. J Cardiol 2011;58:108-15.
4. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Europace 2010;12:1360-420.
5. Vamos M, Hohnloser SH. Amiodarone and dronedarone: An update. Trends Cardiovasc Med 2016 Apr 4. [Epub ahead of print].
6. Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev 2015 Dec 8;(12):CD008093.
7. van Erven L, Schalij MJ. Amiodarone: an effective antiarrhythmic drug with unusual side effects. Heart 2010;96:1593-600.
8. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-34.
9. Kalus JS. Pharmacologic management of atrial fibrillation: established and emerging options. J Manag Care Pharm 2009;15(6 Suppl B):S10-8.
10. Ahmad S. Amiodarone and lipid disorder [letter]. Arch Intern Med 1995; 155: 1912.
11. Pollak PT, Sharma AD, Carruthers SG. Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol 1988; 62: 562-5.
12. Zgazarova S, Jedlickova H, Vasku V. Unwanted skin effects of amiodaron. Vnitr Lek 2009;55(10):976-80.
13. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a metaanalysis of randomized controlled trials. Eur Heart J 2009;30:1245-53.
14. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation.J Am Coll Cardiol 1989;13:442-9.
15. Le Heuzey JY, De Ferrari GM, Radzik D et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605
16. Ehrlich C, Tsu LV. Updates in antiarrhythmic therapy for atrial fibrillation in geriatric patients. Consult Pharm 2015;30(2):82-91.
17. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007; 71: 1610-6.
18. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41.
19. Beers Criteria Update Expert Panel. American Geriatric Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63(11):2227-46.
20. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008;37(6):673-9.
21. O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-8.
22. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36(41):2793-867.
23. Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013;127(18):1916-26.
24. Karamichalakis N, Letsas KP, Vlachos K, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag 2015;11:555-62.
25. Deneer VH, van Hemel NM. Is Antiarrhythmic Treatment in the Elderly Different? A Review of the Specific Changes.Drugs Aging 2011;28(8):617-33.
26. Frishman WH, Aronow WS. Pharmacology of Antiarrhythmic Drugs in Elderly Patient. Clin Geriatr Med 2012;28(4):575-615.
27. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26(6):421-38.
28. Kubesova HM, Weber P, Meluzinova H, et al. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013;125(15-16):425-36.
29. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49: 373-8.
30. Tadros R, Nattel S, Andrade JG. Dronedarone: Basic Pharmacology and Clinical Use. Card Electrophysiol Clin 2016;8(2):453-65.
31. Rochetaing A, Barbe´ C, Kreher P. Beneficial effects of amiodarone and dronedarone (SR33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters assessed during reperfusion in isolated rat hearts. J Cardiovasc Pharmacol 2001;38:500-11.
32. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357(10):987-99.
33. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol 2008;19(11):1220-26.
34. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf 2012;11(6):1023-45.
35. Food and Drug Administration. FDA Drug Safety Communication: severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Checked by 12.08.2016.
36. Piccini JP, Hasselblad V, Peterson ED et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-95.
37. Nattel S. Dronedarone in atrial fibrillation - Jekyll and Hyde? (editorial). N Engl J Med 2011;365:2321.
38. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110(4):607-13.
39. Connolly SJ, Camm AJ, Halperin JL, et al, for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
40. Hohnloser SH, Crijns HJ, van EM, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
41. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007;41(4):599-605.
42. ElMaghawry M, Farouk M. Dronedarone-digoxin interaction in PALLAS: A foxglove connection? Glob Cardiol Sci Pract 2015;2015:4.
43. The Institute for Safe Medication Practices. QuarterWatch: 2010 Quarter 1. Signals for Acetaminophen, dronedarone and Botulinum Toxin Products. Available at: http://www.ismp.org/quarterwatch/2010Q1.pdf. Checked by 12.08.2016.
44. Food and Drug Administration. Labeling revision: highlights of prescribing information (Multaq). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/ 022425s002lbl.pdf. Checked by 12.08.2016.
45. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012;125:381-9.
46. Korantzopoulos P1, Letsas KP, Kotsia A, et al. Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients. World J Cardiol 2013;5(7):242-6.
47. Reiffel JA. Ibutilide as a Torsade de Pointes Stress Test. J Am Coll Cardiol 2016;67(23):2806.
48. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91(6A):15D-26D.
49. Torp-Pedersen C, Møller M, Block-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341(12):857-65.
50. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation 2006;114(7):e257-354.
51. Lang ES, Browning K. Ventricular tachyarrhythmias (out-of-hospital cardiac arrests). BMJ Clin Evid 2010;2010.
52. Wauters M, Elseviers M, Vaes B, et al. Mortality, hospitalisation, institutionalisation in community-dwelling oldest old: The impact of medication. Arch Gerontol Geriatr 2016;65:9-16.
53. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64:369-37.
54. Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76:281-292.
55. Wang YC, Hsieh TC, Chou CL, et al. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine (Baltimore) 2016;95(2)2487.
56. Lewin JJJ3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36:1546-9.
Рецензия
Для цитирования:
Ушкалова Е.А., Зырянов С.К., Затолочина К.Э., Переверзев А.П., Чухарева Н.А. Применение антиаритмических средств у пожилых пациентов. Препараты III и IV классов по классификации Вогана-Вильямса. Рациональная Фармакотерапия в Кардиологии. 2016;12(5):603-609. https://doi.org/10.20996/1819-6446-2016-12-5-603-609
For citation:
Ushkalova E.A., Zyryanov S.K., Zatolochina K.E., Pereverzev A.P., Chukhareva N.A. Antiarrhythmic Drugs Use in Elderly Patients. Vaughan Williams Class III and IV Drugs. Rational Pharmacotherapy in Cardiology. 2016;12(5):603-609. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-5-603-609
Просмотров:
5879
Послать статью по эл. почте 